Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

PURPOSE: We performed a systematic review to define the relative and absolute risk of clinically relevant adverse events with the antiplatelet agents, aspirin and clopidogrel. MATERIALS AND METHODS: Databases were searched for randomized controlled trials of low-dose aspirin (75-325 mg/dayay) or clopidogrel administered for cardiovascular prophylaxis. Relative risks (RR) were determined by meta-analysis of 22 trials for aspirin versus placebo and from single studies for aspirin versus clopidogrel, aspirin versus aspirin/clopidogrel, and clopidogrel versus aspirin/clopidogrel. Absolute risk increase was calculated by multiplying RR increase by the pooled weighted incidence of the control. RESULTS: Aspirin increased the risk of major bleeding (RR = 1.71; 95% confidence interval [CI], 1.41-2.08), major gastrointestinal (GI) bleeding (RR = 2.07; 95% CI, 1.61-2.66), and intracranial bleeding (RR = 1.65; 95% CI, 1.06-5.99) versus placebo. No difference between 75-162.5 mg/day and > 162.5-325 mg/day aspirin versus placebo was seen. The absolute annual increases attributable to aspirin were major bleeding: 0.13% (95% CI, 0.08-0.20); major GI bleeding: 0.12% (95% CI, 0.07-0.19), intracranial bleeding: 0.03% (95% CI, 0.01-0.08). No study compared clopidogrel with placebo. One study showed increased major GI bleeding (but not non-GI bleeding endpoints) with aspirin versus clopidogrel (RR = 1.45; 95% CI, 1.00-2.10). The absolute annual increase was 0.12% (95% CI, 0.00-0.28). CONCLUSIONS: Low-dose aspirin increases the risk of major bleeding by similar to 70%, but the absolute increase is modest: 769 patients (95% CI, 500-1250) need to be treated with aspirin to cause one additional major bleeding episode annually. Compared with clopidogrel, aspirin increases the risk of GI bleeding but not other bleeding; however, 883 patients (95% CI, 357-infinity) would need to be treated with clopidogrel versus aspirin to prevent one major GI bleeding episode annually at a cost of over 1 million dollars. (c) 2006 Elsevier Inc. All rights reserved.